Fiche centre
Sunnybrook Health Sciences Centre
Toronto — Canada
Essais liés15clinical trials
VilleTorontolocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07193953
Essais cliniques associés
15| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Monoplace Hyperbaric Chamber (Class III medical device). | Myopathies | Non applicable | NCT06082518 | PCS-HBOT — Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments | ACTIVE_NOT_RECRUITING |
| Inavolisib | Cancer | Phase 3 | NCT06790693 | INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| CBD | Alzheimer | Phase 2 | NCT06014424 | CALM-IT — Cannabidiol Medication Intervention Trial | RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| Floxuridine (FUDR) | Cancer | Phase 2 | NCT07764497 | HAIP-6192 — Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis | RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| Next Generation Dome Helmet Focused Ultrasound | Sclérose latérale amyotrophique | Phase 1 | NCT07193953 | ALSFUS003 — Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07170150 | TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT07191145 | Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) | NOT_YET_RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Perindopril | Alzheimer | Phase 2 | NCT02085265 | Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients | TERMINATED |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| The Ontario Neurodegenerative Disease Research Initiative | Sclérose latérale amyotrophique | À vérifier | NCT04104373 | The Ontario Neurodegenerative Disease Research Initiative | COMPLETED |